Books & Software | Contact Us | Customer Svc | Company Info
Welcome to UnicorMed Forums Sign in | Join | Faq

Coder-To-Coder Forum

Started by miagirl at 10-22-2009 10:54 AM. Topic has 5 replies.

Print Search
Sort Posts:    
   10-22-2009, 10:54 AM
miagirl is not online. Last active: 2/12/2010 11:20:34 PM miagirl

Top 50 Posts
Joined on 01-13-2009
Posts 11
hydration vs therapeutic
When a patient is being treated for hypokalemia and is given an IV infusion of KCL, is this considered a therapeutic infusion (96365) or hydration 96360???
   Report 
   11-04-2009, 9:39 AM
handmaid is not online. Last active: 11/4/2009 4:26:50 PM handmaid

Top 10 Posts
Joined on 09-19-2006
Georgia
Posts 43
Re: hydration vs therapeutic
Potassium (KCl)  is an electolyte so the infusion is considered a hydration infusion.
   Report 
   12-28-2009, 4:33 PM
rockymeet is not online. Last active: 5/3/2011 3:54:49 PM rockymeet

Top 50 Posts
Joined on 09-08-2009
jaipur
Posts 9
Re: hydration vs therapeutic
 handmaid wrote:
Potassium (KCl)  is an electolyte so the infusion is considered a hydration infusion.

Yes he is right nice post thanks for reply :)
our products


   Report 
   06-20-2010, 2:18 AM
ahmudg is not online. Last active: 7/4/2010 10:00:49 AM ahmudg

Top 150 Posts
Joined on 06-19-2010
Posts 3
Re: hydration vs therapeutic
Hydration should be more than 30 minutes as qualify as theuraputic. Hydration less than 30 minutes is not coded
   Report 
   08-06-2010, 7:35 AM
amonialogin is not online. Last active: 8/6/2010 6:29:44 PM amonialogin

Top 150 Posts
Joined on 08-06-2010
Posts 3
Re: hydration vs therapeutic

Folate antagonists were among the first antineoplastic agents to be developed. In 1948, aminopterin was used to induce remission in childhood acute lymphoblastic leukemia (ALL), and the related agent methotrexate (MTX) is still an important component of modern treatment for ALL as well as a number of other hematologic malignancies [1]. MTX was the first drug shown to cure a cancer when given as monotherapy, and single agent MTX remains a cornerstone of treatment for malignant gestational trophoblastic disease [2].

The broad range of antitumor activity seen with MTX is reflected in the large number of malignant conditions for which MTX is a component of the treatment regimen (table 1). Furthermore, in addition to antiproliferative activity, MTX also has antiinflammatory and immunomodulating properties, leading to its use in a wide range of doses for a broad range of therapeutic indications across multiple specialties (table 2).

Definition of high-dose MTX — The side effect profile of MTX varies markedly according to dose. Regimens containing MTX are classified as high, intermediate, or low-dose:

  • Most clinicians reserve the term high-dose MTX (HDMTX) for doses ≥500 mg/m2, as are used for central nervous system (CNS) prophylaxis in patients with leukemia and high-risk lymphoma, and for the treatment of leptomeningeal metastases, primary CNS lymphoma, and osteosarcoma. These regimens deliver an otherwise lethal dose of MTX in a 4 to 36 hour infusion, followed by a two to three day period of multiple leucovorin doses to terminate the toxic effect of MTX (termed leucovorin "rescue"). Successful rescue by leucovorin depends on rapid elimination of MTX by the kidneys, which requires aggressive pretreatment as well as posttreatment hydration and urinary alkalinization. The main toxicities of HDMTX are elevated serum transaminase levels and renal insufficiency, which can delay drug clearance.
  • Doses between 50 and 500 mg/m2, as used for malignant gestational trophoblastic disease (GTD), are considered intermediate-dose MTX. In general, these patients do not require aggressive hydration or urinary alkalinization. Leucovorin rescue is rarely needed with doses ≤250 mg/m2 unless unexpected toxicity is encountered. (See "Malignant gestational trophoblastic disease: Staging and treatment", section on 'Methotrexate with and without leucovorin'.)


download software

   Report 
   09-03-2010, 5:25 AM
amandak695 is not online. Last active: 9/3/2010 4:24:03 PM amandak695

Top 500 Posts
Joined on 09-03-2010
Posts 1
Re: hydration vs therapeutic
 amonialogin wrote:

Folate antagonists were among the first antineoplastic agents to be developed. In 1948, aminopterin was used to induce remission in childhood acute lymphoblastic leukemia (ALL), and the related agent methotrexate (MTX) is still an important component of modern treatment for ALL as well as a number of other hematologic malignancies [1]. MTX was the first drug shown to cure a cancer when given as monotherapy, and single agent MTX remains a cornerstone of treatment for malignant gestational trophoblastic disease [2].

The broad range of antitumor activity seen with MTX is reflected in the large number of malignant conditions for which MTX is a component of the treatment regimen (table 1). Furthermore, in addition to antiproliferative activity, MTX also has antiinflammatory and immunomodulating properties, leading to its use in a wide range of doses for a broad range of therapeutic indications across multiple specialties (table 2).

Definition of high-dose MTX — The side effect profile of MTX varies markedly according to dose. Regimens containing MTX are classified as high, intermediate, or low-dose:

  • Most clinicians reserve the term high-dose MTX (HDMTX) for doses ≥500 mg/m2, as are used for central nervous system (CNS) prophylaxis in patients with leukemia and high-risk lymphoma, and for the treatment of leptomeningeal metastases, primary CNS lymphoma, and osteosarcoma. These regimens deliver an otherwise lethal dose of MTX in a 4 to 36 hour infusion, followed by a two to three day period of multiple leucovorin doses to terminate the toxic effect of MTX (termed leucovorin "rescue"). Successful rescue by leucovorin depends on rapid elimination of MTX by the kidneys, which requires aggressive pretreatment as well as posttreatment hydration and urinary alkalinization. The main toxicities of HDMTX are elevated serum transaminase levels and renal insufficiency, which can delay drug clearance.
  • Doses between 50 and 500 mg/m2, as used for malignant gestational trophoblastic disease (GTD), are considered intermediate-dose MTX. In general, these patients do not require aggressive hydration or urinary alkalinization. Leucovorin rescue is rarely needed with doses ≤250 mg/m2 unless unexpected toxicity is encountered. (See "Malignant gestational trophoblastic disease: Staging and treatment", section on 'Methotrexate with and without leucovorin'.)


download software

Thanks you for the post.



__________________
watch free movies online

   Report 
UnicorMed Forum... » General » Coder-To-Coder ... » Re: hydration vs therapeutic